DnB Asset Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-14,662
| Closed | -$212K | – | 1302 |
|
|
2026
Q1 | $212K | Buy |
+14,662
| New | +$210K | ﹤0.01% | 1137 |
|
|
2025
Q4 | – | Sell |
-46,161
| Closed | -$364K | – | 746 |
|
|
2025
Q3 | $364K | Buy |
46,161
+6,920
| +18% | +$49.2K | ﹤0.01% | 685 |
|
|
2025
Q2 | $225K | Buy |
39,241
+3,722
| +10% | +$24K | ﹤0.01% | 690 |
|
|
2025
Q1 | $290K | Buy |
35,519
+3,077
| +9% | +$28.5K | ﹤0.01% | 690 |
|
|
2024
Q4 | $306K | Sell |
32,442
-231
| -0.7% | -$2.4K | ﹤0.01% | 686 |
|
|
2024
Q3 | $349K | Buy |
32,673
+490
| +2% | +$5.34K | ﹤0.01% | 673 |
|
|
2024
Q2 | $319K | Buy |
32,183
+5,165
| +19% | +$53K | ﹤0.01% | 673 |
|
|
2024
Q1 | $318K | Buy |
27,018
+2,182
| +9% | +$27.9K | ﹤0.01% | 674 |
|
|
2023
Q4 | $352K | Buy |
24,836
+550
| +2% | +$6.25K | ﹤0.01% | 639 |
|
|
2023
Q3 | $295K | Sell |
24,286
-5,903
| -20% | -$76.1K | ﹤0.01% | 652 |
|
|
2023
Q2 | $379K | Buy |
30,189
+8,818
| +41% | +$105K | ﹤0.01% | 645 |
|
|
2023
Q1 | $237K | Buy |
21,371
+3,217
| +18% | +$39.7K | ﹤0.01% | 644 |
|
|
2022
Q4 | $222K | Sell |
18,154
-2,924
| -14% | -$32.9K | ﹤0.01% | 634 |
|
|
2022
Q3 | $220K | Sell |
21,078
-4,617
| -18% | -$51.4K | ﹤0.01% | 641 |
|
|
2022
Q2 | $276K | Buy |
+25,695
| New | +$212K | ﹤0.01% | 647 |
|
|
2022
Q1 | – | Sell |
-22,837
| Closed | -$264K | – | 653 |
|
|
2021
Q4 | $264K | Sell |
22,837
-151,441
| -87% | -$1.69M | ﹤0.01% | 659 |
|
|
2021
Q3 | $1.67M | Buy |
174,278
+149,898
| +615% | +$1.53M | 0.01% | 565 |
|
|
2021
Q2 | $235K | Buy |
+24,380
| New | +$238K | ﹤0.01% | 629 |
|
|
2021
Q1 | – | Sell |
-15,728
| Closed | -$363K | – | 640 |
|
|
2020
Q4 | $363K | Sell |
15,728
-12,822
| -45% | -$262K | ﹤0.01% | 614 |
|
|
2020
Q3 | $403K | Sell |
28,550
-28,218
| -50% | -$411K | ﹤0.01% | 590 |
|
|
2020
Q2 | $856K | Buy |
+56,768
| New | +$692K | 0.01% | 529 |
|
Other funds holding FOLD
DnB Asset Management's FOLD Position: Q2 2026 in Review
DnB Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 14,662 shares — an estimated $212K sold.
DnB Asset Management first reported a position in FOLD in Q2 2020 and held it in 21 quarters. The position peaked at $1.67M in Q3 2021. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- DnB Asset Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- DnB Asset Management sold 14,662 Amicus Therapeutics shares in Q2 2026, an estimated $212K.
- DnB Asset Management first reported a position in Amicus Therapeutics in Q2 2020 and held it in 21 quarters.
- DnB Asset Management's Amicus Therapeutics position peaked at $1.67M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.